Portola Pharmaceuticals

Portola Pharmaceuticals, Inc. discovers and develops therapeutic agents for acute and chronic cardiovascular and autoimmune/inflammatory diseases. Portola's core drug, Andexxa, is currently the only approved reversal agent for Factor Xa inhibitors and has already been approved for marketing in Europe. This drug can rapidly reverse the anticoagulant effects of the Factor Xa inhibitors rivaroxaban and apixaban, controlling severe and uncontrollable bleeding.In addition to Andexxa, Portola is also developing cerdulatinib, a SYK/JAK inhibitor for treating blood cancers. The company’s products include PRT054021, an oral Factor Xa inhibitor used for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist used for treating patients with acute coronary syndrome; for preventing cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. Additionally, the company’s products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and rheumatoid arthritis (RA), as well as certain cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukemia.